The United States Food and Drug Administration (USFDA) has approached Indian pharmaceutical manufacturers to address a critical shortage of ifosfamide, a chemotherapy drug essential for treating testicular cancer, lung cancer,…
India’s pharmaceutical industry supplies roughly 40 percent of the United States’ generic medicines and approximately 20 percent of global demand. Yet behind this impressive export footprint lies a structural vulnerability…
June 2026 marks a pivotal moment for India's generic pharmaceutical industry. From landmark shifts toward women's health therapeutics to explosive growth in the generic GLP-1 market and sweeping drug-quality reforms,…
One of the most common questions international buyers ask about Indian generic medicines is: "Are they really as effective as the original branded drug?" The answer lies in a rigorous…